FirstWord

HearO combines speech signal processing with AI to analyse recordings for signs of fluid accumulation in the lungs.

Some of the firm's portfolio companies will be able to use agentic AI technology for drug discovery and operations automation.

Duke’s biobanks will give Network Bio access to patient samples linked to years of clinical records, helping train AI models for drug discovery and disease detection.

The telehealth company is already in talks with drugmakers about potential partnerships, with plans to use patient data to investigate why some treatments work better for some.

Eli Lilly's two GLP-1 offerings Zepbound (tirzepatide) and Foundayo (orforglipron) will be available via Hims & Hers' consumer platform.

Two late-breaking studies presented at AHA 2026 highlight AI's potential to extend cardiovascular screening and improve diagnostic workflow, while underscoring the continued importance of clinician ov...

Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III PrevenTRON study design specifics for trontinemab ...

HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it wi...

Findings presented at ACR Convergence 2026 reinforce the long-term potential of neuroimmune modulation as a durable treatment approach for people living with rheumatoid arthritisSANTA CLARITA, Calif.,...

vTIME is a pathophysiologically relevant human tumor model that enables evaluation of efficacy and vascular toxicity on one chip, supporting its use in de-risking and accelerating oncology drug develo...